The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat ...

The company is now hoping for an affirmative answer on its application after an unusually turbulent year dealing with U.S.

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...

What's possible when AI models can learn from additional health data modalities to create a more complete understanding of ...

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.

Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers ...

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors ...

Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after ...

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts ...

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...

Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious ...

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to ...